2,054 Shares in Danaher Corporation $DHR Acquired by Caxton Associates LLP

Key Points

• Caxton Associates LLP acquired a new position in Danaher Corporation by purchasing 2,054 shares, valued at approximately $421,000, as reported in its recent 13F filing.
• Danaher reported a quarterly earnings of $1.80 EPS, surpassing the consensus estimate by $0.16 with revenues of $5.94 billion, up 3.4% from the previous year.
• The company declared a quarterly dividend of $0.32 per share, set to be paid on October 31st, translating to an annualized yield of 0.7%.

Caxton Associates LLP purchased a new position in Danaher Corporation (NYSE:DHR - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,054 shares of the conglomerate's stock, valued at approximately $421,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Hills Bank & Trust Co grew its holdings in Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after buying an additional 53 shares during the last quarter. Sageworth Trust Co grew its holdings in Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after buying an additional 54 shares during the last quarter. 1834 Investment Advisors Co. grew its holdings in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after buying an additional 54 shares during the last quarter. Rakuten Securities Inc. grew its holdings in Danaher by 33.3% during the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after buying an additional 56 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC grew its holdings in Danaher by 1.6% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 3,466 shares of the conglomerate's stock valued at $710,000 after buying an additional 56 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

NYSE DHR opened at $190.07 on Friday. The firm has a market capitalization of $136.10 billion, a P/E ratio of 40.44, a P/E/G ratio of 2.72 and a beta of 0.75. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The business's 50-day simple moving average is $201.21 and its 200-day simple moving average is $198.90.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on DHR shares. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Barclays reiterated an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wells Fargo & Company reduced their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Evercore ISI reduced their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.